R G Uzzo

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Adjuvant therapy for high-risk renal cell carcinoma patients
    David A Kunkle
    Department of Urologic Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Urol Rep 8:19-30. 2007
  2. ncbi request reprint Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer
    R G Uzzo
    The Department of Urology, Fox Chase Cancer Centre, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    BJU Int 93:955-60. 2004
  3. ncbi request reprint The T cell death knell: immune-mediated tumor death in renal cell carcinoma
    R G Uzzo
    Department of Immunology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Cancer Res 7:3276-81. 2001
  4. ncbi request reprint The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician
    Robert G Uzzo
    Department of Surgical Oncology, Division of Urology, Fox Chase Cancer Center, Temple University School of Medicine, 7701 Burholme Avenue, Room C308, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:423-36. 2003
  5. ncbi request reprint Mechanism of apoptosis induced by zinc deficiency in peripheral blood T lymphocytes
    V M Kolenko
    Department of Immunology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Apoptosis 6:419-29. 2001
  6. ncbi request reprint Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
    P Makhov
    Department of Surgical Oncology, Fox Chase Cancer Center of Temple University School of Medicine, Philadelphia, PA 19111, USA
    Br J Cancer 110:899-907. 2014
  7. ncbi request reprint Nephron sparing surgery for renal tumors: indications, techniques and outcomes
    R G Uzzo
    Department of Urology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Urol 166:6-18. 2001
  8. ncbi request reprint Inhibition of NFkappaB induces caspase-independent cell death in human T lymphocytes
    R G Uzzo
    Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Biochem Biophys Res Commun 287:895-9. 2001
  9. ncbi request reprint Caspase-dependent and -independent death pathways in cancer therapy
    V M Kolenko
    Department of Immunology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Apoptosis 5:17-20. 2000
  10. ncbi request reprint Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue
    P E Clark
    Urological Institute, Cleveland, Ohio, USA
    Urology 57:252-6. 2001

Collaborators

Detail Information

Publications73

  1. ncbi request reprint Adjuvant therapy for high-risk renal cell carcinoma patients
    David A Kunkle
    Department of Urologic Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Urol Rep 8:19-30. 2007
    ..Additionally, we review data from completed adjuvant RCC trials and highlight relevant ongoing trials...
  2. ncbi request reprint Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer
    R G Uzzo
    The Department of Urology, Fox Chase Cancer Centre, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    BJU Int 93:955-60. 2004
    ....
  3. ncbi request reprint The T cell death knell: immune-mediated tumor death in renal cell carcinoma
    R G Uzzo
    Department of Immunology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Cancer Res 7:3276-81. 2001
    ..In contrast, we demonstrated that tumor cell death mediated by PFN/GrB can be achieved in the absence of functional caspase activity and is accompanied by a dramatic accumulation of nonapoptotic necrotic cells...
  4. ncbi request reprint The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician
    Robert G Uzzo
    Department of Surgical Oncology, Division of Urology, Fox Chase Cancer Center, Temple University School of Medicine, 7701 Burholme Avenue, Room C308, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:423-36. 2003
    ..These studies must be correlated in a rigorous fashion to clinical parameters and outcomes. Progress against this elusive tumor will require a continuous translational dialogue between laboratory and clinical investigators...
  5. ncbi request reprint Mechanism of apoptosis induced by zinc deficiency in peripheral blood T lymphocytes
    V M Kolenko
    Department of Immunology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Apoptosis 6:419-29. 2001
    ..The release of cytochrome c and activation of downstream caspases precedes changes in the mitochondrial transmembrane potential (Delta Psim). Therefore, cytoplasmic and mitochondrial events are critical to this process...
  6. ncbi request reprint Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
    P Makhov
    Department of Surgical Oncology, Fox Chase Cancer Center of Temple University School of Medicine, Philadelphia, PA 19111, USA
    Br J Cancer 110:899-907. 2014
    ..Piperlongumine (PL), a natural alkaloid present in the fruit of the Long pepper, is known to exhibit notable anticancer effects. Here we investigate the impact of PL on Akt/mTOR signalling...
  7. ncbi request reprint Nephron sparing surgery for renal tumors: indications, techniques and outcomes
    R G Uzzo
    Department of Urology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Urol 166:6-18. 2001
    ..Accumulating data in appropriately select patients suggest a long-term functional advantage gained by the maximal preservation of unaffected renal parenchyma without sacrificing cancer control...
  8. ncbi request reprint Inhibition of NFkappaB induces caspase-independent cell death in human T lymphocytes
    R G Uzzo
    Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Biochem Biophys Res Commun 287:895-9. 2001
    ..The availability of downstream caspases appears to determine the mode of cell death in NFkappaB defective cells...
  9. ncbi request reprint Caspase-dependent and -independent death pathways in cancer therapy
    V M Kolenko
    Department of Immunology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Apoptosis 5:17-20. 2000
    ....
  10. ncbi request reprint Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue
    P E Clark
    Urological Institute, Cleveland, Ohio, USA
    Urology 57:252-6. 2001
    ..The quality of life is better for patients with more renal parenchyma remaining after surgery for localized renal cell carcinoma...
  11. pmc Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram
    A Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Prostate Cancer Prostatic Dis 15:374-9. 2012
    ..The aim of this study was to determine the optimal treatment for a patient with newly diagnosed prostate cancer weighing the individual's risk of disease progression against his risk of non-cancer death...
  12. ncbi request reprint Preoperative use of 3D volume rendering to demonstrate renal tumors and renal anatomy
    D M Coll
    Department of Radiology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Radiographics 20:431-8. 2000
    ..Radiologists should be familiar with current indications for nephron-sparing surgery and understand what information is required prior to surgery...
  13. pmc Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis
    P Makhov
    Department of Surgical Oncology, Division of Urology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cell Death Differ 15:1745-51. 2008
    ..Taken together, our findings indicate that zinc-chelating agents may be used to sensitize malignant cells to established cytotoxic agents via downregulation of XIAP...
  14. ncbi request reprint The treatment of non-metastatic prostate cancer with external beam radiation therapy
    E M Horwitz
    Departments of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Minerva Urol Nefrol 56:173-88. 2004
    ..The appropriate use of adjuvant hormones as well as the complications of these treatments will also be discussed...
  15. pmc Radiation dose and late failures in prostate cancer
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 67:1074-81. 2007
    ..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
  16. ncbi request reprint Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005
    ..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
  17. ncbi request reprint Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study
    Surena F Matin
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Urol 176:1973-7. 2006
    ..To our knowledge no evidence based guidelines exist for determining how or when followup abdominal imaging should be performed after renal energy ablative therapy...
  18. ncbi request reprint Prior abdominal surgery and radiation do not complicate the retroperitoneoscopic approach to the kidney or adrenal gland
    Rosalia Viterbo
    Department of Urological Oncology, Fox Chase Cancer Center, Temple University Medical Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 174:446-50. 2005
    ..We compared clinical outcomes of the laparoscopic retroperitoneal approach in patients with prior open abdominal surgery with or without radiation to outcomes in those with no surgical history...
  19. ncbi request reprint Renal cell carcinoma: urologists in a new era
    Robert G Uzzo
    J Urol 174:1723-4. 2005
  20. ncbi request reprint Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel
    Ronald J Halbert
    Cerner Life Sciences, Beverley Hills, California, USA
    Cancer 107:2375-83. 2006
    ..The authors convened a panel of medical and urologic oncologists to rate the appropriateness of the main options...
  21. ncbi request reprint A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 29:458-62. 2006
    ..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome...
  22. pmc Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  23. ncbi request reprint Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
    ..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
  24. ncbi request reprint The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1082-7. 2007
    ..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
  25. ncbi request reprint Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses
    David A Kunkle
    Department of Urologic Oncology, Fox Chase Cancer Center, and Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 177:1692-6; discussion 1697. 2007
    ..To better define the relationship between tumor size and the metastatic potential of small renal masses, we investigated whether radiographic tumor size predicts for the presence of synchronous metastases in renal cell carcinoma...
  26. pmc Predicting growth of solid renal masses under active surveillance
    Paul L Crispen
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Urol Oncol 26:555-9. 2008
    ..Here we evaluate factors that may help predict radiographic growth during observation...
  27. pmc Renal masses--to treat or not to treat? If that is the question are contemporary biomarkers the answer?
    Robert G Uzzo
    J Urol 180:433-4. 2008
  28. pmc Residual prostate cancer after radiotherapy: a study of radical cystoprostatectomy specimens
    David J Kaplan
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 72:654-8. 2008
    ..We investigated the relationship between prostate-specific antigen (PSA) and histologically residual CaP after definitive RT in patients undergoing radical cystoprostatectomy (RCP) for unrelated indications...
  29. doi request reprint Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review
    David A Kunkle
    Department of Urologic Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 179:1227-33; discussion 1233-4. 2008
    ..We performed a meta-analysis of published data evaluating nephron sparing surgery, cryoablation, radio frequency ablation and observation for small renal masses to define the current data...
  30. pmc How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 70:1487-91. 2008
    ..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
  31. ncbi request reprint The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 112:55-60. 2008
    ..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
  32. ncbi request reprint Prostate cancer risk assessment program: a 10-year update of cancer detection
    Veda N Giri
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19012, USA
    J Urol 178:1920-4; discussion 1924. 2007
    ..Guidelines for screening men at high risk for prostate cancer remain under investigation. We report our 10-year cancer detection data from the Prostate Cancer Risk Assessment Program, a longitudinal screening program for men at high risk...
  33. pmc Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
    ..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
  34. ncbi request reprint The natural history of untreated renal masses
    Paul L Crispen
    Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA 19111, USA
    BJU Int 99:1203-7. 2007
  35. ncbi request reprint Enhancing renal masses with zero net growth during active surveillance
    David A Kunkle
    Department of Urologic Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 177:849-53; discussion 853-4. 2007
    ..We compared clinical, radiographic and pathological characteristics of enhancing renal masses under active surveillance with zero net radiographic growth vs those with positive growth...
  36. ncbi request reprint Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 62:397-405. 2005
    ..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
  37. doi request reprint Delayed intervention of sporadic renal masses undergoing active surveillance
    Paul L Crispen
    Department of Urological Oncology, Fox Chase Cancer Center, Temple University Medical Center, Philadelphia, PA 19111, USA
    Cancer 112:1051-7. 2008
    ....
  38. ncbi request reprint What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:1003-10. 2005
    ..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
  39. ncbi request reprint The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 100:538-43. 2004
    ..However, there is little direct evidence that dose escalation has an impact on distant metastasis (DM) or overall mortality (OM). These associations were examined in the current study...
  40. ncbi request reprint Brachytherapy for prostate cancer: follow-up and management of treatment failures
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:737-50, viii-ix. 2003
    ..Finally, a comprehensive review of the management of local recurrence following brachytherapy is offered...
  41. ncbi request reprint Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    World J Urol 21:200-8. 2003
    ..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
  42. ncbi request reprint Positive prostate biopsy laterality and implications for staging
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 62:298-303. 2003
    ..Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used...
  43. ncbi request reprint Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 169:2153-7; discussion 2157-9. 2003
    ..We evaluated the impact of backdating on no biochemical evidence of disease (bNED) control and suggest changes in the definition...
  44. ncbi request reprint Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination
    Robert G Uzzo
    Department of Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 61:754-9. 2003
    ....
  45. ncbi request reprint Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Radiother Oncol 66:173-9. 2003
    ....
  46. ncbi request reprint Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy
    Wayne H Pinover
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 97:1127-33. 2003
    ....
  47. ncbi request reprint Renal cell carcinoma invading the urinary collecting system: implications for staging
    Robert G Uzzo
    Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Urol 167:2392-6. 2002
    ..We evaluated the incidence and characteristics as well as overall and cancer specific survival of renal cell carcinoma invading the urinary collecting system...
  48. ncbi request reprint Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
    Khanh H Nguyen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:377-83. 2003
    ....
  49. ncbi request reprint Prostate cancer radiotherapy dose response: an update of the fox chase experience
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 171:1132-6. 2004
    ....
  50. ncbi request reprint Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database
    Mark K Buyyounouski
    J Urol 171:1246-7; author reply 1247. 2004
  51. ncbi request reprint Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 58:743-9. 2004
    ..This is the first description of the ability to limit the dose received by the penile bulb (PB) and corporal bodies (CB) using intensity-modulated radiotherapy (IMRT)...
  52. ncbi request reprint Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:695-701. 2005
    ..To determine whether the radiation dose is a determinant of clinical outcome in patients with a lymph node risk of >15% treated using whole pelvic (WP), partial pelvic (PP), or prostate only (PO) fields...
  53. ncbi request reprint Androgen suppression plus radiation therapy for prostate cancer
    Eric M Horwitz
    JAMA 292:2084-5; author reply 2085. 2004
  54. ncbi request reprint The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
    ....
  55. ncbi request reprint Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy
    Noel M Kramer
    Departments of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    BJU Int 94:59-62. 2004
    ..To compare the outcome of similar patients with prostate cancer treated by either observation or three-dimensional conformal radiation therapy (3-DCRT)...
  56. ncbi request reprint Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1291-8. 2005
    ..The temporal kinetics of posttreatment PSA levels was examined to define the error in the classification of BF...
  57. ncbi request reprint The genetics of renal oncocytosis: a possible model for neoplastic progression
    Tahseen Al-Saleem
    Department of Pathology, Medical Science Division, Human Genetics Program, Populations Sciences Division, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer Genet Cytogenet 152:23-8. 2004
    ..To our knowledge, this is the first report of the genetic and cytogenetic findings in oncocytosis not related to BDH syndrome and may suggest a possible model of progression from oncocytoma to chromophobe renal cell carcinoma...
  58. ncbi request reprint Identification of novel target genes by an epigenetic reactivation screen of renal cancer
    Inmaculada Ibanez de Caceres
    Departments of Surgical Oncology and Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 66:5021-8. 2006
    ....
  59. ncbi request reprint Decision-making strategies for patients with localized prostate cancer
    Michael A Diefenbach
    Department of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19422, USA
    Semin Urol Oncol 20:55-62. 2002
    ..These data suggest that unique treatment-related beliefs and affects need to be taken into account during the treatment counseling process. Implications for the development of decision aids are discussed...
  60. pmc Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo
    Konstantin Golovine
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 10111, USA
    Clin Cancer Res 14:5376-84. 2008
    ..In this study, we investigate the functional effect of hZIP1 overexpression on NF-kappaB activity and tumorigenic potential in human prostate cancer cells in vitro and in vivo...
  61. ncbi request reprint Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention
    Paul L Crispen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Prostate 67:582-90. 2007
    ..NF-kappaB and AP-1 transcriptional factors contribute to the development and progression of prostate malignancy by regulating the expression of genes involved in proliferation, apoptosis, angiogenesis, and metastasis...
  62. pmc Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway
    Konstantin Golovine
    Department of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 68:1443-9. 2008
    ....
  63. ncbi request reprint Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents
    Robert G Uzzo
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 8:3579-83. 2002
    ..These results suggest one possible mechanism for the inhibitory effect of zinc on the development and progression of prostate malignancy and might have important consequences for the prevention and treatment of prostate cancer...
  64. pmc Pathologic concordance of sporadic synchronous bilateral renal masses
    Jason Rothman
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 72:138-42. 2008
    ....
  65. ncbi request reprint Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients
    Cristina Battagli
    Departments of Surgical Oncology and Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:8695-9. 2003
    ..Methylation-specific PCR may enhance early detection of renal cancer using a noninvasive urine test...
  66. ncbi request reprint Cutaneous metastases from genitourinary malignancies
    Thomas J Mueller
    Department of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 63:1021-6. 2004
    ..Among patients with urologic malignancies, the incidence and appearance of cutaneous metastases are not well established and recognition is poor among practicing urologists...
  67. ncbi request reprint Promoter hypermethylation profile of kidney cancer
    Essel Dulaimi
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:3972-9. 2004
    ..To gain insight into the role of epigenetic silencing of tumor suppressor and cancer genes in kidney tumorigenesis, we determined a hypermethylation profile of kidney cancer...
  68. ncbi request reprint The natural history of observed enhancing renal masses: meta-analysis and review of the world literature
    Sam N Chawla
    Department of Urologic Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 175:425-31. 2006
    ..Data on the natural history of untreated enhancing renal lesions is limited but could serve as a decision making resource for patients and physicians. We examined available data on the natural history of observed solid renal masses...
  69. ncbi request reprint Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression
    Robert G Uzzo
    Department of Urological Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Carcinogenesis 27:1980-90. 2006
    ..Upregulation of intracellular zinc levels may have important implications for inhibiting the angiogenic and metastatic potentials of malignant cells, predominantly through suppression of NF-kappaB signaling...
  70. ncbi request reprint Targeted therapies for kidney cancer in urologic practice
    Naomi B Haas
    Department of Medical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA 19111, USA
    Urol Oncol 25:420-32. 2007
    ..We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician...
  71. ncbi request reprint Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer
    Naomi B Haas
    Department of Medical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Treat Options Oncol 8:211-26. 2007
    ..Here we review the molecular pathways that define the pertinent therapeutic targets in RCC and the clinical data for these new and promising agents...
  72. ncbi request reprint Shared decision-making strategies for early prostate cancer
    John T Wei
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, MI 48109 0330, USA
    Semin Urol Oncol 20:74-8. 2002
    ..We present a unified platform for shared decision-making strategies regarding prostate cancer in clinical practice...
  73. ncbi request reprint Prostate cancer and the educated consumer
    Robert G Uzzo
    Semin Urol Oncol 20:1-2. 2002